EZH2 and neoplasm: Inactivation of EZH2 has been demonstrated to reverse resistance and enhance the efficacy of immunotherapies.212 Moreover, a recent study utilizing CRISPR-Cas9 screens to target chromatin regulators in mouse tumor models has identified the H3K9 methyltransferase SETDB1 as a key mediator of immune evasion.